PFS
Figure 2 · Panel _A_
Panel _A_ 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Andrew J Armstrong, Hilary Dietz, David Balli, William J Geese, Chunzhe Duan, Yu-Han Hung, Virginia Ip, Gerald Li, Ryon P Graf, Neal Ready
Clin Cancer Res 31(24) 5198-5210
PURPOSE: Low-density lipoprotein receptor-related protein 1b (LRP1b) is a cell surface receptor, commonly altered in many cancers and associated with improved responses, progression-free survival (PFS), and overall survival with immune checkpoint inhibition. EXPERIMENTAL DESIGN: LRP1b alterations were determined by whole-exome sequencing and associated with PFS and objective response rates in patients with non-small cell lung cancer (NSCLC) in a post hoc analysis of the randomized controlled phase III CheckMate-026 (CM026) trial (NCT02041533) examining chemotherapy compared with nivolumab, adjusting for tumor mutational burden (TMB) and clinical features. We separately evaluated a deidentified nationwide (US-based) NSCLC clinico-genomic database for associations of LRP1b alterations and PFS with anti-PD-1 immunotherapy. RESULTS: In the clinico-genomic database cohort of patients with NSCLC (N = 18,369), LRP1b mutations were positively associated with TP53/KRAS alterations and inversely with EGFR/RET/MET/ERBB2 alterations and significantly improved PFS with PD-1 inhibition (n = 1,569; adjusted HR, 0.86; P = 0.014). In CheckMate-026, patients with LRP1b alterations had a statistically significant improvement in objective response rate to nivolumab versus LRP1b wild-type patients (OR 3.5; 95% confidence interval, 1.71-7.13; P = 0.0006) but not with chemotherapy (OR 0.63; 95% confidence interval, 0.32-1.26; P = 0.19), adjusting for TMB, age, gender, histology, smoking, and performance status. LRP1b mutations were associated with improved PFS with nivolumab (HR, 0.66; P = 0.04) but not chemotherapy (HR, 1.26; P = 0.25), also maintained in multivariate and TMB-adjusted analyses. CONCLUSIONS: LRP1b mutations are a candidate predictive biomarker for immune checkpoint inhibition versus chemotherapy in NSCLC. Further mechanistic characterization of LRP1b and prospective validation are warranted and might enable future clinical use.
2 个 Figure · 6 个 KM 面板
Figure 2. Univariable associations of LRP1b and TMB in patients with NSCLC treated with single-agent anti-PD1 axis therapies. Outcome associations are visualized with Kaplan-Meier plots stratified by (A) any LRP1b alteration, (B) known or likely functional LRP1b status, (C) variant of unknown significance LRP1b status, and (D) by TMB10.
Figure 2 · Panel _A_
Panel _A_ 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel _B_
Panel _B_ 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel _C_
Panel _C_ 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel _D_
Panel _D_ 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5. Evaluation of predictive value of LRPb1 mutation in CM026. (A) Univariate and multivariate analyses of ORR in nivolumab vs chemotherapy arms. (B-C) Kaplan-Meier plots of nivolumab vs chemotherapy by LRP1b status for the outcome of PFS. (D) Univariate and multivariate analyses of PFS in nivolumab vs chemotherapy arms. Multivariate analysis adjusts for age, sex, smoking history, performance status and histology.
这些图片未产生 KM 曲线结果,不在主页面重复展示。